Circulating biomarkers and their possible role in pathogenesis of chronic hepatitis B and C viral infections

Indian Journal of Clinical Biochemistry

Volumn 26, Issue 2, 2011, Pages 161-168

  Khan, Saba ^a   Bhargava, Arpit ^a,b   Pathak, Neelam ^a   Maudar, Kewal K ^a   Varshney, Subodh ^a   Mishra, Pradyumna K ^a,b  

^a BHOPAL MEMORIAL HOSPITAL AND RESEARCH CENTRE   (India)

^b TATA MEMORIAL HOSPITAL   (India)

Author keywords

Biomarkers; Hepatitis; Hepatocellular carcinoma; Nucleosomes; Translational research

Indexed keywords

EID: 84878834425     PISSN: 09701915     EISSN: 09740422     Source Type: Journal    
DOI: 10.1007/s12291-010-0098-7     Document Type: Article

References (43)

1. Hepatitis B. Vaccines. Wkly Epidemiol Rec. 2004;9:255-63.
2. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112-25. (Pubitemid 44289094)
3. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13:2436-41. (Pubitemid 46929498)
4. Modlin RL, Nutman TB. Type 2 cytokines and negative immune regulation in human infections. Curr Opin Immunol. 1993;5:511-4.
5. NIH Consensus Statement on Management of Hepatitis C. NIH Consens State Sci Statements. 2002;19:1-46.
6. Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol. 1998;10:2381-91. (Pubitemid 28464295)
7. Fan XG, Liu WE, Li CZ, Wang ZC, Luo LX, Tan DM, et al. Circulating Th1 and Th2 cytokines in patients with hepatitis C virus infection. Mediators Inflamm. 1998;7:295-7. (Pubitemid 28419525)
8. Ramadori G, Armbrust T. Cytokines in the liver. Eur J Gastroenterol Hepatol. 2001;13:777-84. (Pubitemid 32656590)
9. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res. 2001;61:4365-70. (Pubitemid 32685760)
10. Hoek JB, Pastorino JG. Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol. 2002;27:63-8. (Pubitemid 34626486)
11. Farinati F, Cardin R, Degan P, De Maria N, Floyd RA, Van Thiel DH, et al. Oxidative DNA damage in circulating leukocytes occurs as an early event in chronic HCV infection. Free Radic Biol Med. 1999;27:1284-91. (Pubitemid 30001490)
12. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73. (Pubitemid 43042691)
13. Mishra PK, Bhargava A, Khan S, Pathak N, Punde RP, Varshney S. Prevalence of hepatitis C virus genotypes and impact of T helper cytokines in achieving sustained virological response during combination therapy: a study from Central India. Indian J Med Microbiol. 2010;28:358-62.
14. Mishra PK, Khan S, Bhargava A, Panwar H, Banerjee S, Jain SK, et al. Regulation of isocyanate-induced apoptosis, oxidative stress, and inflammation in cultured human neutrophils: isocyanate-induced neutrophils apoptosis. Cell Biol Toxicol. 2010;26:279-91.
15. Mishra PK, Raghuram GV, Panwar H, Jain D, Pandey H, Maudar KK. Mitochondrial oxidative stress elicits chromosomal instability after exposure to isocyanates in human kidney epithelial cells. Free Radic Res. 2009;43:718-28.
16. Bhargava A, Punde RP, Pathak N, Dabadghao S, Desikan P, Jain A, et al. Status of inflammatory biomarkers in the population that survived the Bhopal gas tragedy: a study after two decades. Ind Health. 2010;48:204-8.
17. Bhargava A, Khan S, Panwar H, Pathak N, Punde RP, Varshney S, et al. Occult hepatitis B virus infection with low viremia induces DNA damage, apoptosis and oxidative stress in peripheral blood lymphocytes. Virus Res. 2010;153:143-50.
18. Mishra PK, Dabadghao S, Modi GK, Desikan P, Jain A, Mittra I, et al. In utero exposure to methyl isocyanate in the Bhopal gas disaster: evidence of persisting hyperactivation of immune system two decades later. Occup Environ Med. 2009;66:279.
19. Alacacioglu A, Somali I, Simsek I, Astarcioglu I, Ozkan M, Camci C, et al. Epidemiology and survival of hepatocellular carcinoma in Turkey: outcome of multicenter study. Jpn J Clin Oncol. 2008;38:683-8.
20. Fan XG, Yakkob J, Fan XJ, Keeling PW. Enhanced Th2 responses: immune mechanism of H. pylori infection. Ir J Med Sci. 1996;165:37-9. (Pubitemid 26082385)
21. Jirillo E, Greco B, Caradonna L, Satalino R, Pugliese V, Cozzolongo R, et al. Evaluation of cellular immune responses and soluble mediators in patients with chronic hepatitis C virus (cHCV) infection. Immunopharmacol Immunotoxicol. 1995;17:347-64.
22. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre-and post treatment with interferon alfa. Hepatology. 1996;24:6-9. (Pubitemid 26249404)
23. Piazzolla G, Tortorella C, Schiraldi O, Antonaci S. Relationship between interferon-gamma, interleukin-10, and interleukin-12 production in chronic hepatitis C and in vitro effects of interferon-alpha. J Clin Immunol. 2000;20:54-61. (Pubitemid 30210107)
24. Song LH, Binh VQ, Dinh ND, Kun JF, Bock TC, Kremsner PG, et al. Serum cytokine profiles associated with clinical presentation in Vietnamese infected with hepatitis B virus. J Clin Virol. 2003;28:93-103. (Pubitemid 36970109)
25. Clerici M, Shearer GM. TH1-TH2 switch is a critical step in the etiology of HIV infection. Immunol Today. 1993;14:107-10.
26. Hsia CY, Huo TI, Chiang SY, Lu MF, Sun CL, Wu JC, et al. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg Oncol. 2007;33:208-12.
27. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805-12. (Pubitemid 38057722)
28. Shrive AK, Cheetham GM, Holden D, Myles DA, Turnell WG, Volanakis JE, et al. Three dimensional structure of human C-reactive protein. Nat Struct Biol. 1996;3:346-54. (Pubitemid 26112633)
29. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov. 2003;2:566-80. (Pubitemid 37361748)
30. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004;279:48487-90. (Pubitemid 39625721)
31. Clearfield MB. C-reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc. 2005;105:409-16. (Pubitemid 41603444)
32. Di Napoli M, Papa F. C-reactive protein and cerebral small-vessel disease: an opportunity to reassess small-vessel disease physiopathology? Circulation. 2005;112:781-5. (Pubitemid 41170061)
33. Lin ZY, Wang LY, Yu ML, Chen SC, Chuang WL, Hsieh MY, et al. Role of serum C-reactive protein as a marker of hepatocellular carcinoma in patients with cirrhosis. J Gastroenterol Hepatol. 2000;15:417-21.
34. Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Torimura T, Adachi H, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int. 2007;27:1091-7. (Pubitemid 47399443)
35. Patel T. Apoptosis in hepatic pathophysiology. Clin Liver Dis. 2000;4:295-317. (Pubitemid 30460826)
36. Liu DX. A new hypothesis of pathogenetic mechanism of viral hepatitis B and C. Med Hypotheses. 2001;56:405-8.
37. Holdenrieder S, Eichhorn P, Beuers U, Samtleben W, Schoenermarck U, Zachoval R, et al. Nucleosomal DNA fragments in autoimmune diseases. Ann N Y Acad Sci. 2006;1075:318-27. (Pubitemid 44532800)
38. Swietek K, Juszczyk JJ. Reduced glutathione concentration in erythrocytes of patients with acute and chronic viral hepatitis. J Viral Hepat. 1997;4:139-41. (Pubitemid 127736549)
39. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 3rd ed. Oxford: Science Publications; 1999.
40. Chrobot AM, Szaflarska-Szczepanik A, Drewa G. Antioxidant defense in children with chronic viral hepatitis B and C. Med Sci Monit. 2000;6:713-8.
41. Tanyalcin T, Taskiran D, Topalak O, Batur Y, Kutay F. The effects of chronic hepatitis C and B virus infections on liver reduced and oxidized glutathione concentrations. Hepatol Res. 2000;18:104-9. (Pubitemid 30458680)
42. Demirdag K, Yilmaz S, Ozdarendeli A, Ozden M, Kalkan A, Kilic SS. Levels of plasma malondialdehyde and erythrocyte antioxidant enzyme activities in patients with chronic hepatitis B. Hepatogastroenterology. 2003;50:766-70. (Pubitemid 36613401)
43. Maki A, Kono H, Gupta M, Asakawa M, Suzuki T, Matsuda M, et al. Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol. 2007;14:1182-90.